A descriptive analysis of real-world treatment patterns of innovator (Remicade^®) and biosimilar infliximab in an infliximab-naïve Turkish population

References

• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• MainiRSt ClairEWBreedveldFInfliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupLancet199935491941932193910622295
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345151098110411596589
   PubMed Web of Science ®Google Scholar
• de KeyserFInfliximab in Ankylosing SpondylitisDrugs200565912921294
   Web of Science ®Google Scholar
• GottliebABInfliximab for psoriasisJ Am Acad Dermatol2003492 Suppl112117
   Web of Science ®Google Scholar
• AntoniCMangerBInfliximab for psoriasis and psoriatic arthritisClin Exp Rheumatol2002206 Suppl 28S12212512463461
   PubMed Web of Science ®Google Scholar
• MckeageKA review of CT-P13: an infliximab biosimilarBioDrugs201428331332124723086
   PubMed Web of Science ®Google Scholar
• BlairHADeeksEDInfliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory DiseasesBioDrugs201630546948027650650
   PubMed Web of Science ®Google Scholar
• JhaAUptonADunlopWCAkehurstRThe Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European CountriesAdv Ther201532874275626343027
   PubMed Web of Science ®Google Scholar
• Biosimilar infliximab receives approval in Japan and TurkeyGaBI Online2014 Available from: http://www.gabionline.net/Biosimilars/News/Biosimilar-infliximab-receives-approval-in-Japan-and-Turkey. AccessedAccessed January 15, 2018
   Google Scholar
• ParkWHrycajPJekaSA randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnn Rheum Dis201372101605161223687259
   PubMed Web of Science ®Google Scholar
• GlintborgBKringelbachTHøgdallENon-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio RegistryAnn Rheum Dis201675224
   Web of Science ®Google Scholar
• YooDHProdanovicNJaworskiJEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyAnn Rheum Dis201776235536327130908
   PubMed Web of Science ®Google Scholar
• TursiAAllegrettaLChiriSEffectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real-life experience in IBD primary centersMinerva Gastroenterol Dietol201763431331828293938
   PubMed Web of Science ®Google Scholar
• DeianaSGabbaniTAnneseVBiosimilars in inflammatory bowel disease: A review of post-marketing experienceWorld J Gastroenterol201723219728127193
   PubMed Web of Science ®Google Scholar
• DaneseSFiorinoGRaineTECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An UpdateJ Crohns Colitis2017111263427927718
   PubMed Web of Science ®Google Scholar
• HernandezLDRodriguez GonzalezGEVela GonzalezMEfficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 monthsEuropean Crohn’s and Colitis OrganisationClinical: Therapy and ObservationAmsterdam, Netherlands2016 Available from: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2016/item/p449-efficacy-and-safety-of-switching-between-originator-and-biosimilar-infliximab-in-patients-with-inflammatory-bowel-disease-in-practical-clinic-results-to-6x00a0months.htmlAccesed July 30, 2018
   Google Scholar
• KangYSMoonHHLeeSELimYJKangHWClinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case SeriesDig Dis Sci201560495195625326115
   PubMed Web of Science ®Google Scholar
• SmitsLJDerikxLAde JongDJClinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort StudyJ Crohns Colitis201610111287129327095751
   PubMed Web of Science ®Google Scholar
• NikiphorouEKautiainenHHannonenPClinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opin Biol Ther201515121677168326549204
   PubMed Web of Science ®Google Scholar
• BálintARutkaMVéghZFrequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohortExpert Opin Drug Saf201716888589028504555
   PubMed Web of Science ®Google Scholar
• GlintborgBKringelbachTMHøgdallENon-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis-impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio registry17th Annual European Congress of Rheumatology2016London, UK
   Google Scholar
• BaserOBaserEAltinbasABurkanASeverity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in TurkeyHealth Econ Rev201331523497510
   PubMedGoogle Scholar
• BaserOBurkanABaserEKoselerliRErtugayEAltinbasADirect medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims DatabaseRheumatol Int201333102577258423708559
   PubMed Web of Science ®Google Scholar
• Republic of Turkey Prime Ministry Investment Support and Promotion Agency Available from: http://www.invest.gov.tr/enUS/infocenter/publications/Documents/HEALTHCARE.INDUSTRY.pdfAccessed January 15, 2018
   Google Scholar
• Republic of Turkey Statistical Institute. TurkStatThe results of address based population registration system 20112012 Available from: http://www.turkstat.gov.tr/PreHaberBultenleri.do?id=10736Accessed January 15, 2018
   Google Scholar
• SeiterACelikYTurkey: Pharmaceutical Sector Analysis2008 Available from: https://www.researchgate.net/publication/242581202_Accessed January 15, 2018
   Google Scholar
• GlintborgBSørensenIJLoftAGA nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnn Rheum Dis20177681426143128473425
   PubMed Web of Science ®Google Scholar